This article is more than 5 years old. Information may no longer be current.
Masket IOL negates dysphotopsia
Click Here to Manage Email Alerts
SAN DIEGO — No patients reported negative dysphotopsia after implantation of the Morcher 90S IOL, the production model of an anti-dysphotopic IOL, according to the technology’s patent holder, Samuel Masket, MD.
Masket reported initial clinical results of implantation of the anti-dysphotopsia IOL in 38 cases at the American Society of Cataract and Refractive Surgery meeting. Follow-up to date is between 1 and 18 months.
Negative dysphotopsia can be prevented, relieved or improved when the IOL optic edge overlies the anterior capsule, Masket said.
“The design concept is to place this groove [of the IOL] on the anterior edge of the optic, allowing the capsulotomy to be captured in this groove,” he said. “In this fashion you’ve got the optic overlying the capsule rather than the capsule overlying the optic, and the bulk of the lens is still placed in the capsular bag.” The concept allows for any haptic design or any edge design, and allows for routine surgery, he added.
Of the 38 lenses, 28 were implanted using femtosecond laser. Ten cases were performed manually.
“This lens will be well suited for femtosecond laser having an automated capsulotomy, but a measured rhexis could also work. There is growing interest in lenses that are held in place, in fact, by an automated capsulotomy,” Masket said.
The lens failed to capture the capsulotomy in two cases, two patients had capsule block, and no patients had iris chafe.
According to a non-validated questionnaire, 37 patients would have the same lens again and no patients exhibited any type of negative dysphotopsia. – by Kristie L. Kahl
Disclosure: Masket reports he is consultant for Alcon, MST Surgical, Ocular Therapeutix, PowerVision, VisionCare Ophthalmic Technologies and WaveTec Vision; an investor for Ocular Therapeutix; and earns royalties from Morcher GmbH and Haag-Streit AG.